Is STVN a good stock to buy? We came across a bullish thesis on Stevanato Group S.p.A. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls’ thesis on STVN. Stevanato Group S.p.A.’s share was trading at $18.10 as of June 9th. STVN’s trailing and forward P/E were 30.80 and 19.46 respectively according to Yahoo Finance.
Looker_Studio/Shutterstock.com
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa and internationally. STVN delivered a strong Q4 performance, significantly beating consensus expectations and reinforcing the company’s underlying growth trajectory.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Reported revenue grew 5% versus consensus of 0.8%, while organic growth reached 7% compared to low single-digit expectations, driven by robust execution in its high-value solutions segment. Growth was led by Biopharmaceutical and Diagnostic Solutions, with High-Value Solutions expanding 31% year over year, offsetting continued weakness in engineering.
Importantly, Stevanato Group disclosed that GLP-1 related revenue represented approximately 19–20% of total sales and grew over 50%, reducing prior market fears of excessive exposure to oral GLP-1 disruption. Management further guided GLP-1 revenues to mid-teens growth in 2026, implying sustained demand rather than deterioration. Based on this, non-GLP operations are expected to grow around 7%, underscoring a more balanced and diversified growth profile than previously assumed.
The company guided 2026 organic growth of 9% at midpoint, which appears conservative given historical underestimation patterns and Q4 outperformance. Engineering remains a laggard but is increasingly immaterial relative to accelerating high-value segments. Capital expenditure of €280 million, or roughly 21% of sales, is largely growth-oriented, with 89% allocated to expansion supporting long-term HVS demand across Fishers and Latina facilities.
While near-term free cash flow remains subdued, Stevanato Group’s steady capacity build-out implies structurally higher future earnings power and an estimated mid-single-digit free cash flow yield on normalized levels. With improving margins, strong biologics demand, and reduced GLP-1 overhang, Stevanato Group is positioned for sustained compounding driven by durable high-value healthcare packaging leadership going forward with confidence.
Previously, we covered a bullish thesis on Stevanato Group S.p.A. (STVN) by Best Anchor Stocks’ Substack in May 2025, which highlighted Q1 revenue beat and HVP-led margin expansion potential. STVN’s stock price has depreciated by approximately 19.94% since our coverage. Best Anchor Stocks’ Substack shares a similar view but emphasizes GLP-1 visibility and Capex-driven long-term compounding.
Stevanato Group S.p.A. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held STVN at the end of the first quarter which was 15 in the previous quarter. While we acknowledge the risk and potential of STVN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than STVN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
